REG - Proteome Sciences - Two Further Substantial Contracts for PRM

Proteome SciencesAnnouncement

06/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260106:nRSF7240Na&default-theme=true

RNS Number : 7240N  Proteome Sciences PLC  06 January 2026

 

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
UK Market Abuse Regulations. With the publication of this announcement, this
information is now considered to be in the public domain.

6  January 2026

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Two further substantial contracts for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that following the
Company's announcement dated 8 December 2025, the Company has secured two
further substantial Good Clinical Laboratory Practice ("GCLP") contracts. The
contracts have a combined value in excess of $1.5m.  Trial samples are
expected to be shipped in late Q1 this year, with the major part of the
contracts completed in 2026.

Commenting on the contracts, Richard Dennis, Chief Commercial Officer of
Proteome Sciences said:

"We continue to experience strong interest in GCLP work from major biopharma
clients in both the US and Europe and expect further orders to materialise in
due course. These new contracts together with contracts previously secured
provide a strong order book supporting our business  through  2026."

- Ends -

For further information:

 Proteome Sciences plc
 Dr. Ian Pike, Chief Scientific Officer    Tel: +44 (0)20 7043 2116
 Richard Dennis, Chief Commercial Officer

 SP Angel Corporate Finance LLP  (Nominated Adviser & Broker)
 David Hignell/Richard Morrisom/Josh Ray  (Corporate Finance)   Tel: +44 (0) 20 3470 0470

 Vadim Alexandre (Corporate Broking)

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUPUWAGUPQPGA



            Copyright 2019 Regulatory News Service, all rights reserved